4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms

Acute Myeloid Leukemia (AML) & Related Neoplasms

Acute Myeloid Leukemia (AML) is a clonal hematopoietic stem cell malignancy characterized by the uncontrolled proliferation and accumulation of poorly differentiated myeloid progenitor cells (blasts) in the bone marrow, peripheral blood, and other tissues. This malignant proliferation suppresses normal hematopoiesis, causing rapid-onset bone marrow failure manifested by severe anemia, neutropenia, and thrombocytopenia.

                      ACUTE MYELOID LEUKEMIA (AML)
                                   │
         ┌─────────────────────────┴─────────────────────────┐
         ▼                                                   ▼
DIAGNOSTIC CRITERIA & MORPHOLOGY                    CYTOGENETICS & CYTOCHEMISTRY
  • Blast threshold: ≥20% marrow/blood                • Recurrent Genetic Abnormalities:
    (Exception: <20% if defining genetics)                - APL with PML::RARA [t(15;17)]
  • Myeloblast features: high N:C, delicate               - AML with RUNX1::RUNX1T1 [t(8;21)]
    chromatin, 2–5 nucleoli, primary granules             - AML with CBFB::MYH11 [inv(16)]
  • Auer rods: Fused primary azurophilic                  - AML with KMT2A [11q23.3]
    granules (MPO+); pathognomonic for                • Cytochemical Staining Profile:
    myeloid lineage (NEVER in ALL)                        - MPO & Sudan Black B (+)
                                                          - Specific Esterase / CAE (+)
                                                          - Non-Specific Esterase / NSE (+ NaF-sensitive)

---

1. Diagnostic Criteria & Blast Thresholds (WHO 5th Edition & ICC 2022)

Under current World Health Organization (WHO 5th Edition) and International Consensus Classification (ICC 2022) frameworks, diagnosing Acute Myeloid Leukemia requires fulfilling defined quantitative blast thresholds or identifying disease-defining recurrent genetic abnormalities:

1. Standard Blast Threshold: The presence of $\ge 20%$ blasts (myeloblasts, monoblasts, promonocytes, or megakaryoblasts) in the bone marrow nucleated differential or peripheral blood leukocyte count.
2. Genetically-Defined AML Exceptions (Diagnosed Regardless of Blast Count): When specific recurrent chromosomal translocations are identified, the diagnosis of AML is established even if the blast count is $<20%$:
   • AML with $PML::RARA$ fusion [$t(15;17)(q24.1;q21.2)$]
   • AML with $RUNX1::RUNX1T1$ fusion [$t(8;21)(q22;q22.1)$]
   • AML with $CBFB::MYH11$ fusion [$\text{inv}(16)(p13.1q22)$ or $t(16;16)(p13.1;q22)$]
   • Note on ICC Guidelines: ICC allows AML classification for other recurrent fusions (e.g., KMT2A, DEK::NUP214) with a blast threshold of $\ge 10%$.

---

2. Cytomorphology of Myeloblasts & Pathognomonic Auer Rods

Accurate identification of blast cytomorphology on Romanowsky / Wright-Giemsa stained marrow and peripheral blood films is the foundation of leukemia diagnosis:

                    MYELOBLAST CYTOMORPHOLOGY

  ┌─────────────────────────────────────────────────────────┐
  │ Size: 15–20 µm (Moderate to Large)                      │
  │ Nucleus: Round, oval, or slightly indented              │
  │ Chromatin: Fine, delicate, lacey, unaggregated          │
  │ Nucleoli: 2 to 5 distinct, pale, prominent nucleoli     │
  │ Cytoplasm: Moderate basophilic cytoplasm, agranular     │
  │            or containing sparse azurophilic granules    │
  │ Hallmarks: AUER RODS (Pathognomonic for Myeloid Lineage)│
  └─────────────────────────────────────────────────────────┘

Auer Rods: Ultrastructure and Lineage Specificity

• Biochemical Composition: Auer rods are elongated, needle-like, or cylindrical crystalline cytoplasmic inclusions formed by the abnormal aggregation and fusion of primary (azurophilic / lysosomal) granules. They contain concentrated crystalline myeloperoxidase (MPO), lysosomal acid phosphatase, and chloroacetate esterase.
• Diagnostic Pearl: Auer rods are pathognomonic for neoplasms of the myeloid lineage (AML, Myelodysplastic Syndromes with excess blasts). They are NEVER present in Acute Lymphoblastic Leukemia (ALL) or mature lymphoid malignancies.

---

3. AML with Recurrent Genetic Abnormalities

                    RECURRENT GENETIC SUBTYPES OF AML
                                    │
        ┌─────────────────┬─────────┴─────────┬─────────────────┐
        ▼                 ▼                   ▼                 ▼
   PML::RARA         RUNX1::RUNX1T1      CBFB::MYH11         KMT2A (MLL)
   [t(15;17)]          [t(8;21)]          [inv(16)]          [11q23.3]
  • Hypergranular     • Large Auer rods   • Abnormal marrow   • Monoblastic /
    promyelocytes     • Salmon-pink         eosinophils         monocytic
  • Faggot cells        granules            (purple-violet)   • Tissue invasion
  • Severe DIC risk   • CD19 aberrant     • Myelomonocytic      (gingiva, skin)
  • ATRA + ATO tx     • Favorable         • Favorable         • Poor prognosis

1. Acute Promyelocytic Leukemia (APL) with $PML::RARA$ [$t(15;17)(q24.1;q21.2)$]

• Molecular Genetics: Reciprocal translocation fusing the Promyelocytic Leukemia gene (PML) on chromosome 15q24.1 with the Retinoic Acid Receptor Alpha gene (RARA) on chromosome 17q21.2. The resulting PML-RARA chimeric protein acts as a dominant-negative transcriptional repressor, binding nuclear corepressor complexes (HDACs) to block physiological promyelocyte differentiation.
• Cytomorphology:
  • Classic Hypergranular APL: Markedly abnormal promyelocytes with reniform, bilobed, or butterfly-shaped nuclei and cytoplasm packed with heavy, coarse azurophilic granules. Characterized by pathognomonic "faggot cells" containing dense bundles, sheaves, or clusters of multiple Auer rods crisscrossing the cytoplasm.
  • Microgranular (Hypogranular) Variant: Blasts exhibit deeply folded, convoluted, cerebriform, or bilobed nuclei resembling monocytes with sparse, submicroscopic granules. Characterized by high leukocyte counts ($>50 - 100 \times 10^9\text{/L}$) and rapid kinetics.
• Medical Emergency & Consumptive Coagulopathy: APL is the most urgent hematologic emergency due to life-threatening Disseminated Intravascular Coagulation (DIC) and hyperfibrinolysis. Abnormal promyelocytes express high levels of tissue factor (TF), cancer procoagulant, and annexin II (a cell-surface receptor for plasminogen and tPA), precipitating massive thrombin generation, fibrinogen consumption, elevated D-dimer, and fatal intracranial or pulmonary hemorrhage.
• Targeted Therapy: Immediate administration of All-Trans Retinoic Acid (ATRA / Tretinoin) in combination with Arsenic Trioxide (ATO) induces conformational changes, degrades the PML-RARA oncoprotein, and triggers terminal differentiation of malignant promyelocytes into mature neutrophils, curing $>90%$ of patients without traditional cytotoxic chemotherapy.

2. AML with $RUNX1::RUNX1T1$ [$t(8;21)(q22;q22.1)$]

• Molecular Genetics: Translocation fusing the RUNX1 (AML1) gene on 21q22 with the RUNX1T1 (ETO) gene on 8q22.1, generating a chimeric transcriptional repressor that halts myeloid differentiation.
• Morphology: Large myeloblasts with abundant basophilic cytoplasm, prominent perinuclear hofs, large single Auer rods with tapered ends, and distinctive salmon-pink / pseudo-Chediak cytoplasmic granules. Often demonstrates dysplastic maturing neutrophils with abnormal nuclear lobulation.
• Immunophenotypic Signature: Expresses pan-myeloid markers (CD13, CD33, CD34, CD117, MPO) with characteristic aberrant co-expression of B-cell lineage markers: CD19 and PAX5, alongside CD56.
• Prognosis: Highly favorable prognosis with high complete remission rates when treated with high-dose cytarabine consolidation.

3. AML with $CBFB::MYH11$ [$\text{inv}(16)(p13.1q22)$ or $t(16;16)(p13.1;q22)$]

• Molecular Genetics: Pericentric inversion of chromosome 16 or translocation fusing the Core-Binding Factor Beta gene (CBFB) at 16q22 with the smooth muscle Myosin Heavy Chain 11 gene (MYH11) at 16p13.1.
• Morphology: Acute myelomonocytic leukemia with bone marrow eosinophilia (formerly FAB M4Eo). Characterized by a dual proliferation of myeloblasts and monoblasts accompanied by abnormal bone marrow eosinophils containing large, coarse, purple-violet / basophilic immature granules mixed with normal specific eosinophilic granules.
• Prognosis: Highly favorable prognosis; belongs to the core-binding factor (CBF) leukemia family alongside $t(8;21)$.

4. AML with $KMT2A$ ($MLL$) Rearrangement [11q23.3]

• Molecular Genetics: Translocations involving the KMT2A (Lysine Methyltransferase 2A / Mixed Lineage Leukemia / MLL) gene on chromosome 11q23.3, partnering with over 80 different partner genes (most commonly $t(9;11)(p22;q23.3)$ partnering with MLLT3).
• Morphology & Lineage: Predominantly monoblastic or monocytic leukemia (FAB M5a/M5b). Blasts show abundant cytoplasm with pseudopodia, delicate folded/convoluted nuclei, fine lacey chromatin, and intense non-specific esterase positivity.
• Clinical Hallmarks: High propensity for extramedullary tissue infiltration, including marked gingival hypertrophy, cutaneous leukemia cutis (violaceous skin nodules), hepatosplenomegaly, and central nervous system (CNS) infiltration. Carries an intermediate to poor prognosis (except $t(9;11)$ which has intermediate risk).

---

4. Cytochemical Staining in AML Differentiation

Cytochemical stains detect specific cellular enzymes or biochemical constituents within blast cytoplasm, providing definitive lineage assignment prior to or complementing flow cytometry:

                      CYTOCHEMICAL STAINING MATRIX
                                    │
         ┌──────────────────────────┼──────────────────────────┐
         ▼                          ▼                          ▼
  MYELOPEROXIDASE (MPO)      SPECIFIC ESTERASE (CAE)    NON-SPECIFIC ESTERASE (NSE)
  • Primary azurophilic      • Naphthol AS-D            • Alpha-naphthyl acetate/butyrate
    granules                   chloroacetate              substrate
  • Granulocytic lineage     • Granulocytic lineage     • Monocytic lineage (Monoblasts)
  • Brown-black precipitate  • Bright red/blue color    • INHIBITED by Sodium Fluoride (NaF)
  • SBB stains identically   • Negative in monocytes    • Dual esterase: Differentiates M4

1. Myeloperoxidase (MPO)

• Biochemical Principle: Myeloperoxidase is a lysosomal heme enzyme located in primary (azurophilic) granules of granulocytes and lysosomes of monocytes. In the presence of hydrogen peroxide ($H_2O_2$), MPO oxidizes a benzidine-derived chromogen (e.g., 3,3'-diaminobenzidine / DAB) to form an insoluble, stable brown-to-black granular deposit.
• Lineage Specificity: Strongly positive in myeloblasts, promyelocytes, and maturing granulocytes. Monocytes show weak, finely dispersed positivity. Lymphoblasts, erythroblasts, and megakaryoblasts are strictly MPO-negative.
• Diagnostic Criterion: Demonstration of $\ge 3%$ MPO-positive blasts definitively establishes myeloid lineage.

2. Sudan Black B (SBB)

• Principle: A lipophilic dye that partitions into intracellular lipids, phospholipids, sterols, and neutral fats contained within primary and secondary granulocytic granules.
• Diagnostic Utility: Stains parallel to MPO. SBB is particularly valuable because it can stain older or stored specimens where enzymatic MPO activity has degraded, and it is less sensitive to fixative inactivation.

3. Specific Esterase (SE / Chloroacetate Esterase / CAE)

• Principle: Uses naphthol AS-D chloroacetate as a substrate. The cellular enzyme hydrolyzes the ester bond, liberating free naphthol compounds that couple with a diazonium salt to produce a bright red or blue insoluble precipitate.
• Lineage Specificity: Marker of the granulocytic (neutrophilic) lineage (present from myeloblasts through mature segmented neutrophils). Mast cells are also strongly positive. Strictly negative in monocytic and lymphoid lineages.

4. Non-Specific Esterase (NSE / $\alpha$-Naphthyl Acetate or Butyrate)

• Principle: Uses $\alpha$-naphthyl acetate or $\alpha$-naphthyl butyrate as substrate to identify non-specific carboxylic esterases distributed diffusely throughout the cytoplasm.
• Lineage Specificity: Strongly, diffusely positive in monoblasts, promonocytes, monocytes, and macrophages. Granulocytic precursors are negative or show only weak, focal staining.
• Sodium Fluoride (NaF) Inhibition Test: When sodium fluoride is added to the incubation medium, monocytic NSE activity is completely inhibited (inactivated), abolishing the stain. In contrast, the weak focal NSE activity seen in granulocytes, megakaryocytes, or focal dot T-lymphocytes is fluoride-resistant. NaF sensitivity is the definitive proof of monocytic differentiation.

5. Dual Esterase Staining (CAE + NSE Combined)

• Dual esterase staining combines Specific Esterase (CAE) and Non-Specific Esterase (NSE) on a single peripheral blood or bone marrow slide using contrasting chromogens (e.g., blue for CAE and reddish-brown for NSE). This allows simultaneous, distinct visualization and enumeration of granulocytic and monocytic blast populations in Acute Myelomonocytic Leukemia (AML-M4).